Skip to content

HBV DNA Levels During Pregnancy in Chronic Hepatitis B

Serial HBV DNA Levels During Pregnancy in Patients With Chronic Hepatitis B: a Prospective Observational Follow-up Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01610115
Enrollment
100
Registered
2012-06-01
Start date
2012-01-31
Completion date
2014-12-31
Last updated
2012-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Pregnancy

Keywords

Pregnancy

Brief summary

To elucidate the natural course of chronic hepatitis B by serial HBV DNA and alanine aminotransferase (ALT) levels during pregnancy

Detailed description

This is a prospective observational follow-up study in a single center. Number of patients: It is estimated to enroll 100 patients in Taiwan. Population: Female patients with pregnancy confirmed, at least 20 years of age diagnosed with chronic hepatitis B. The patients are able to communicate well, provide informed consent and willing to participate in the entire study. Inclusion criteria: Patients must meet all of the following criteria 1. Documented chronic hepatitis B defined by clinical history compatible with chronic hepatitis B and detectable serum HBsAg 2. Female 20 years of age with confirmed pregnancy 3. Willing and able to comply with all the requirements in the observational followup study 4. Willing and able to provide written informed consent to participate in the study Exclusion criteria: Patients will be excluded from the study for any of the following reasons: 1. Concurrent infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) 2. One or more known primary or secondary causes of liver disease other than hepatitis B (e.g., alcoholism, non-alcoholic steatohepatitis, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease). 3. Any other concurrent medical or psychosocial condition likely to preclude compliance with the schedule of evaluations in the protocol or likely to confound the efficacy or safety observations of the study. 4. Enrolled or planning to enroll in another clinical trial of an investigational agent while participating in this study. 5. Patients with antiviral therapy to chronic hepatitis B

Interventions

None listed

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Documented chronic hepatitis B defined by clinical history compatible with chronic hepatitis B and detectable serum HBsAg 2. Female 20 years of age with confirmed pregnancy 3. Willing and able to comply with all the requirements in the observational follow-up study 4. Willing and able to provide written informed consent to participate in the study

Exclusion criteria

1. Concurrent infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) 2. One or more known primary or secondary causes of liver disease other than hepatitis B (e.g., alcoholism, non-alcoholic steatohepatitis, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease). 3. Any other concurrent medical or psychosocial condition likely to preclude compliance with the schedule of evaluations in the protocol or likely to confound the efficacy or safety observations of the study. 4. Enrolled or planning to enroll in another clinical trial of an investigational agent while participating in this study. 5. Patients with antiviral therapy to chronic hepatitis B

Countries

Taiwan

Contacts

Primary ContactMei-Hsia Ku
kuvicky1029@gmail.com886-3-3281200
Backup ContactYi-Cheng Chen
yichengliver@gmail.com886-3-3281200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026